ArticleDiabetologia2026
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisWe investigated the association between continuous glucose monitoring (CGM) and acute and chronic diabetes-related complications and mortality risk in adults with type 1 diabetes.
methodsThis study included adults with type 1 diabetes who received intensive insulin therapy, based on data from the Korean National Health Insurance Service Cohort (2016-2022). The primary outcomes were diabetic ketoacidosis (DKA), severe hypoglycaemia (SH), end-stage kidney disease (ESKD), cardiovascular disease (CVD) and all-cause mortality. Between-group analyses (comparing outcomes between CGM users and non-users) were conducted using Cox proportional hazards regression models, and within-group analyses (comparing outcomes before and after CGM initiation) were performed using paired t tests.
resultsA total of 17,018 individuals (8509 CGM users and 8509 non-users) were included. CGM users had lower rates of DKA (adjusted hazard ratio [aHR] 0.40; 95% CI 0.33, 0.48), ESKD (aHR 0.43; 95% CI 0.32, 0.56), CVD (aHR 0.28; 95% CI 0.23, 0.33) and all-cause mortality (aHR 0.38; 95% CI 0.32, 0.46) than non-users. The aHR for SH was comparable between the two groups (aHR 0.92; 95% CI 0.77, 1.10 for users vs non-users). However, among CGM users, the mean frequency of SH decreased by 61.5% after CGM initiation (p<0.001). The frequencies of DKA and CVD-related hospitalisation or emergency department visits also decreased by 60.0% and 50.0%, respectively (p<0.001 for both). CONCLUSIONS/
interpretationIn this nationwide cohort study of adults with type 1 diabetes, CGM users had lower rates of both acute and chronic diabetes-related complications and all-cause mortality compared with non-users.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.